SAN DIEGO, April 01, 2023 (GLOBE NEWSWIRE) Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced publication in The Lancet of the interim analysis of efficacy and safety data from the ongoing pivotal
Travere Therapeutics (TVTX) Announces Data Presentations of Interim Analysis from Phase 3 PROTECT Study of FILSPARI streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
SAN DIEGO, March 23, 2023 Travere Therapeutics, Inc. today announced that the interim analysis of efficacy and safety data from the ongoing Phase 3 PROTECT Study evaluating. | March 23, 2023
Travere Therapeutics Announces Late-Breaker Presentations of the Interim Analysis from the Phase 3 PROTECT Study of FILSPARI™ (Sparsentan) in IgA Nephropathy at the ISN World Congress of Nephrology and NKF Spring Clinical Meetings 2023 forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.